-
Limitation on manufacturer liability for downstream overcharging.
-
Simplified pricing procedures for subsequent launches of new drugs.
-
Heightened record retention obligations introduced for companies.
INTRODUCTION
The Department of Pharmaceuticals ("DoP") has notified the Drugs (Prices Control) Amendment Order, 20261 ("Amendment Order"), introducing several important changes to the Drugs (Prices Control) Order, 2013 ("DPCO").
While many of the amendments appear procedural in nature, their implications for pharmaceutical manufacturers are significant. The amendments narrow manufacturer exposure to downstream overcharging, formalise compliance pathways for implementation of price revisions, simplify launch procedures for follow-on products and provide greater flexibility in relation to price fixation.
Collectively, the reforms indicate a shift away from blanket manufacturer liability and towards a more proportionate and compliance-based pricing framework, where regulatory protections are increasingly linked to demonstrable compliance with dissemination and recordkeeping obligations.
BACKGROUND
Under the earlier DPCO framework, manufacturers often remained exposed to overcharging liability across the supply chain even where pricing violations occurred at the level of distributors or retailers and outside the manufacturer's direct control. Similarly, manufacturers launching products for which prices had already been fixed by the National Pharmaceutical Pricing Authority ("NPPA") continued to be subject to separate approval requirements prior to launch.
The DPCO also contained limited guidance regarding the precise manner in which revised prices were to be disseminated across the supply chain and the extent to which compliance with such obligations could mitigate liability arising from downstream non-compliance.
The Amendment Order seeks to address these concerns by introducing clearer dissemination obligations, reducing procedural duplication and aligning liability more closely with the party responsible for the pricing violation.
DIFFERENTIAL PRICING FORMALISED
Under the pre-amendment framework, the DPCO did not expressly contemplate separate ceiling prices or retail prices for the same formulation based on factors such as pack size, dosage form or content type, often resulting in uncertainty and reliance upon administrative practice.
The Amendment Order now expressly permits separate ceiling prices or retail prices to be notified for the same drug based upon differences in pack size, dosage form, strength or content characteristics, provided there is an appropriate therapeutic or regulatory rationale.
The amendment introduces greater commercial flexibility for manufacturers and formally recognises differentiated pricing structures which had previously operated in a one size fits all approach for the finished drug formulations.
OVERCHARGING LIABILITY STREAMLINED
Under the earlier framework, manufacturers could potentially be held liable for overcharged stock across the market even where the actual overcharging occurred at the level of distributors, stockists or retailers after products had already entered the distribution chain.
The Amendment Order substantially narrows this exposure by restricting liability to the quantity of stock actually handled by the distributor, retailer or stockist found to have sold the product above the applicable ceiling price (plus local taxes as applicable).
However, this protection is conditional upon manufacturers demonstrating compliance with the dissemination obligations prescribed under Paragraph 24 of the DPCO.
This represents one of the most significant changes introduced by the Amendment Order and reflects a move towards a more proportionate allocation of liability based on actual responsibility for the pricing violation.
PRESCRIBED SAFE HARBOUR FOR PRICE REVISIONS
While Paragraph 24 previously required manufacturers to communicate price changes to dealers and retailers, the DPCO did not prescribe a detailed compliance framework capable of limiting liability arising from downstream overcharging.
The Amendment Order now introduces a defined compliance pathway requiring manufacturers to undertake prescribed dissemination measures following price reductions, including:
-
circulation of revised price lists including Form V and Form VI to dealers and retailers immediately and not later than two weeks of the date of such notification;
-
advertisement of price reductions in at least two national newspapers immediately and not later than two weeks of the date of such notification;
-
creation and maintenance of dedicated DPCO price related disclosures sections on the company’s website; and
-
submitting batch-wise production details and stock position of the scheduled formulations held by the company and distributors at the time of price revision.
Manufacturers that comply with these requirements within the prescribed timelines may benefit from restricted liability limited to the stock handled by the defaulting distributor or retailer rather than exposure across the broader market inventory.
The amendment therefore transforms dissemination obligations from a procedural requirement into a critical compliance and liability management exercise.
FOLLOW-ON PRODUCT LAUNCHES SIMPLIFIED
Previously, manufacturers launching a new drug were required to obtain separate retail price approval from the NPPA even where the retail price for the same new drug had already been fixed for another manufacturer within the preceding twelve months as of the date of intended launch of the new drug.
The Amendment Order now permits second and subsequent manufacturers launching the same new drug within twelve months of the first retail price fixation to proceed without obtaining a fresh approval.
Manufacturers are only required to intimate the launch to the authorities through the newly introduced Form IA within one month of such commercial launch.
The amendment removes an important procedural bottleneck and is expected to reduce launch timelines for follow-on products, particularly in competitive generic markets where speed to market is commercially significant.
RECORD RETENTION REQUIREMENTS EXPANDED
The Amendment Order also significantly expands record preservation obligations under the DPCO.
While the earlier framework did not prescribe a long-term record retention requirement, manufacturers are now required to maintain production and sales records for at least seven financial years preceding the current financial year and for longer periods where any proceedings have been initiated or remain pending in respect of the manufacturer under the DPCO.
The enhanced retention obligations reflect the increasing importance of auditability and verification under the DPCO, particularly given that access to the newly introduced liability protections may depend upon a manufacturer's ability to demonstrate compliance with price information dissemination requirements.
POLICY IMPLICATIONS AND INDUSTRY IMPACT
The amendments represent an important shift in the philosophy of pharmaceutical price regulation in India.
Rather than imposing broad liability upon manufacturers for pricing violations occurring throughout the supply chain, the revised framework increasingly links regulatory exposure to demonstrable compliance with dissemination, communication and documentation obligations.
Manufacturers that can establish timely implementation of revised prices and maintain adequate records stand to benefit from significantly reduced financial exposure in downstream overcharging proceedings. Conversely, the effectiveness of the newly introduced protections will depend heavily upon documentation discipline and the ability to establish compliance retrospectively.
The amendments are also likely to influence commercial arrangements between manufacturers, distributors and retailers, with increased emphasis expected on contractual protections, audit rights, stock reporting obligations and pricing compliance mechanisms.
Taken together, the reforms indicate a broader policy move towards proportionate enforcement and supply chain accountability, while preserving the DPCO's core objective of ensuring affordability and accessibility of medicines.
While the amendments reduce procedural friction in several areas, the benefits are closely linked to robust dissemination practices, effective record management and greater visibility across the distribution chain. For pharmaceutical manufacturers, pricing compliance is therefore increasingly becoming as much an exercise in documentation and supply chain governance as it is in price fixation itself.
Shlok Siddhant, Tanya Kukade and Dr. Milind Antani
You can direct your queries or comments to the authors.
1 Accessible at: https://nppa.gov.in/storage/uploads/tender/dpco-amend-2026-02-07-2026.pdf